A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis

Abstract Background Airway inflammation, mediated in part by LTB4 , contributes to lung destruction in patients with cystic fibrosis (CF). LTB4 -receptor inhibition may reduce airway inflammation. We report the results of a randomized, double-blind, placebo-controlled study of the efficacy and safet...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of cystic fibrosis 2014-03, Vol.13 (2), p.148-155
Hauptverfasser:	Konstan, M.W, Döring, G, Heltshe, S.L, Lands, L.C, Hilliard, K.A, Koker, P, Bhattacharya, S, Staab, A, Hamilton, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Amidines - administration & dosage Amidines - adverse effects Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - adverse effects Anti-inflammatory therapy Bronchoalveolar Lavage Fluid Carbamates - administration & dosage Carbamates - adverse effects Child Clinical trial Cystic fibrosis Cystic Fibrosis - diagnosis Cystic Fibrosis - drug therapy Cystic Fibrosis - metabolism Cystic Fibrosis - physiopathology Disease Progression Double-Blind Method Drug Monitoring - methods Drug-Related Side Effects and Adverse Reactions - etiology Drug-Related Side Effects and Adverse Reactions - physiopathology Early Termination of Clinical Trials Female Humans Inflammation - drug therapy Inflammation - metabolism Inflammation - physiopathology Leukotriene B4 receptor antagonist Lung disease Male Pulmonary/Respiratory Receptors, Leukotriene B4 - antagonists & inhibitors Receptors, Leukotriene B4 - metabolism Respiratory Function Tests - methods Risk Assessment Sputum - drug effects Sputum - metabolism Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!